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Abstract
Background—Exercise training is recommended for chronic heart failure (HF) patients to
improve functional status and reduce risk of adverse outcomes. Elevated plasma levels of amino-
terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP),
and cardiac troponin T (cTnT) are associated with increased risk of adverse outcomes in this
patient population. Whether exercise training leads to improvements in biomarkers and how such
improvements relate to clinical outcomes are unclear.
Methods and Results—Amino-terminal pro-brain natriuretic peptide, hs-CRP, and cTnT levels
were assessed at baseline and 3 months in a cohort of 928 subjects from the HF-ACTION study, a
randomized clinical trial of exercise training versus usual care in chronic HF patients with reduced
left ventricular ejection fraction (<35%). Linear and logistic regressions were used to assess 3-
month biomarker levels as a function of baseline value, treatment assignment (exercise training vs
usual care), and volume of exercise. Linear regression and Cox proportional hazard modeling were
used to evaluate the relations between changes in biomarker levels and clinical outcomes of
interest that included change in peak oxygen consumption (peak VO2), hospitalizations, and
mortality. Exercise training was not associated with significant changes in levels of NT-proBNP
(P = .10), hs-CRP (P = .80), or detectable cTnT levels (P = .83) at 3 months. Controlling for
baseline biomarker levels or volume of exercise did not alter these findings. Decreases in plasma
concentrations of NT-proBNP, but not hs-CRP or cTnT, were associated with increases in peak
VO2 (P < .001) at 3 months and decreased risk of hospitalizations or mortality (P ≤ .04), even
after adjustment for a comprehensive set of known predictors.
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Conclusions—Exercise training did not lead to meaningful changes in biomarkers of
myocardial stress, inflammation, or necrosis in patients with chronic HF. Only improvements in
NT-proBNP translated to reductions in peak VO2 and reduced risk of clinical events.
Both the 2012 European Society of Cardiology and 2013 American College of Cardiology
Foundation/American Heart Association guidelines for diagnosis and management of heart
failure (HF) recommend exercise training or regular physical activity for HF patients, to
improve functional status and reduce risk of hospitalization (class 1/level of evidence: A).1,2
These recommendations were largely based on the definitive trial of exercise in HF—HF-
ACTION—that randomly assigned 2,331 chronic systolic HF patients to either exercise
training or usual care for 3 months and showed an 11% reduction in all-cause mortality,
cardiovascular disease mortality, or hospitalizations in the exercise training group.
Therefore, although exercise might be beneficial in this patient population, contemporary
evaluations to gauge disease stability are quite imprecise; as a result, biomarkers reflecting
molecular processes involved in the pathophysiology of HF are increasingly used as clinical
tools for disease management.3 There is significant evidence in support of using amino-
terminal pro-brain natriuretic peptide (NT-proBNP) levels for prognosis (class I/A) and to
guide outpatient therapy in HF (class IIa/B) and emerging evidence in the case of cardiac
troponin and high-sensitivity C-reactive protein (hs-CRP) levels.1,4
Despite the centrality of exercise as a patient-centered intervention in HF and the
increasingly routine use of biomarkers to follow HF patients, the effects of exercise on
commonly measured cardiovascular biomarkers have never been assessed in a randomized
controlled exercise training trial of HF patients with quantitative measures of exercise
performance and cardiovascular fitness. Nonetheless, the positive effects of exercise on
cardiovascular biomarkers, particularly on natriuretic peptides levels, have been propagated
in the literature, likely due to results from small trials, observational studies, and plausible
presupposition.5
To definitively examine this hypothesis, we sought to examine the independent effects of
exercise training on plasma levels of NT-proBNP, hs-CRP, and cardiac troponin T (cTnT) in
a cohort of 928 chronic HF patients who participated in the HF-ACTION trial. We also
investigated the relationship between longitudinal improvements in plasma biomarker
levels, functional status, and clinical outcomes.
Methods
Study population
Details of the design, rationale, and primary results of the HF-ACTION study have been
published elsewhere.6,7 Briefly, HF-ACTION (clinicaltrials.gov: NCT00047437) was a
randomized clinical trial evaluating the effect of exercise training versus usual care on long-
term morbidity and mortality in 2,331 patients with chronic HF due to left ventricular
systolic dysfunction (New York Heart Association [NYHA] classes II-IV, left ventricular
ejection fraction [LVEF] <35%).
Exercise testing
Patients were randomized to either (1) usual HF care or (2) a structured, group-based,
supervised exercise program, with a goal of 3 sessions per week for a total of 36 sessions in
3 months. During the supervised training phase, patients performed walking, treadmill, or
stationary cycling as their primary training mode. Exercise was initiated at 15 to 30 minutes
per session at a heart rate corresponding to 60% of heart rate reserve (maximal heart rate on
cardiopulmonary exercise test minus resting heart rate) and ramped up. Patients in the
exercise training group were also provided home exercise equipment, and home exercise
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adherence and amount were formally measured. Patients in the usual care group were not
provided with a formal exercise prescription. All patients, regardless of treatment group,
received detailed self-management educational materials that included information on
medications, fluid management, symptom exacerbation, sodium intake, and amount of
activity recommended by the American College of Cardiology and American Heart
Association guidelines.8 Cardiopulmonary exercise testing and a 6-minute walk test were
performed at baseline and at 3 months.
Clinical end points
The primary end point of HF-ACTION was a composite of all-cause mortality and all-cause
hospitalization over a median follow-up of 2.5 years. An independent clinical events
committee adjudicated all deaths and first hospitalizations. Additional end points of interest
were all-cause mortality, the composite end point of cardiovascular mortality or
cardiovascular hospitalization, and the composite end point of cardiovascular mortality or
HF hospitalization. HF-ACTION was approved by local institutional review boards, and all
enrolled patients provided written informed consent.
Biomarker measurements
A subset of patients enrolled in the HF-ACTION study agreed to participate in the
biomarker substudy and underwent plasma collection at baseline, 3 months, and 12 months.
The current analysis was performed on patients with data available on all 3 biomarkers (NT-
proBNP, hs-CRP, and cTnT) at baseline and 3 months (n = 928). Blood samples were
obtained on the same day as exercise testing but were obtained before exercise. Samples
were collected via peripheral vein into EDTA containing tubes and then centrifuged
immediately and stored at −70°C for subsequent analysis. Amino-terminal pro-brain
natriuretic peptide, hs-CRP, and cTnT were measured using enzyme-linked immunosorbent
assays (Roche Diagnostics, Indianapolis, IN).9-11 All testing was performed at academic
core laboratory blinded to clinical data.
Statistical analysis
Baseline characteristics were described using medians and intraquartile ranges or
proportions, according to treatment group (usual case vs exercise training). Differences were
compared using Fisher exact and Wilcoxon rank sum tests for continuous variables and χ2
tests for categorical variables. The outcome variables of interest included the clinical
outcomes summarized above as well as the changes in peak oxygen consumption (peak
VO2) from baseline to 3 months. To examine the associations between exercise training and
improvements in biomarker levels at 3 months, linear and logistic regression models were fit
to assess 3-month levels as a function of baseline level and treatment assignment (exercise
training vs usual care). Amino-terminal pro-brain natriuretic peptide and hs-CRP levels were
considered as continuous variables and log transformed for analysis because they were not
normally distributed. Because cTnT was only detectable in 14% of subjects, it was modeled
as a dichotomous variable, stratified at the lower limit of detection for the assay (high >0.01
ng/mL, low ≤0.01 ng/mL). To assess the effect of exercise volume, patients in the exercise
training arm were grouped according to achieved levels of exercise: low exercise (<3 MET-
hours/week), moderate exercise (3-7 MET-hours/week), and high exercise (>7 MET-hours/
week).12 The association between volume of exercise and improvements in biomarker levels
at 3 months was examined by replacing treatment assignment with categorized exercise
volume in the linear model described above. Next, linear and Cox proportional hazards
regression models were fit to examine the association between improvement in 3-month
biomarker levels and outcomes. Improvements in NT-proBNP and hs-CRP were defined as
a numerical decrease in biomarker level from baseline measurement. Improvements in cTnT
were defined as categorical changes from high at baseline to low at 3 months. To examine
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the association between improvements in biomarker levels and change in peak VO2, a linear
regression model was fit to assess 3-month levels as a function of baseline peak VO2 level
and an indicator of biomarker improvement as defined above. To examine the association
between improvement in biomarker levels and the remaining outcomes, Cox proportional
hazard models landmarked at 3 months were fit that modeled time-to-first event as a
function of the baseline biomarker measurement and an indicator for improvement in
biomarker level between baseline and 3 months. Adjustments were made using a previously
identified set of predictors for each outcome of interest that had been identified in the final
adjusted model for the overall HF-ACTION cohort (see online Appendix for final adjusted
model for each end point). All analyses were performed with SAS 9.2 (SAS Institute
Incorporated, Cary, NC) and R 12.15.1 (R Development Core Team; R Foundation for
Statistical Computing, Vienna, Austria). P ≤ .05 was considered statistically significant for
all analyses. The authors had full access to and take full responsibility for the integrity of the
data.
Dr Ahmad received support from the Daland Fellowship in Clinical Investigation. The HF-
ACTION study was funded by grants from the National Heart, Lung, and Blood Institute.
The biomarkers assays were funded by a grant from Roche Diagnostics. No other extramural
funding was used to support this work. The authors are solely responsible for the design and




Baseline and 3-month plasma levels of NT-proBNP, hs-CRP, and cTnT were available for
928 patients, who were broadly similar to the HF-ACTION cohort as a whole (n = 2,331,
Supplementary Table I). Patient characteristics of this cohort, as a whole and according to
randomization group, are shown in Table I. Median age of the study cohort was 59 years; of
these, 63% were white, and 71% were male. Most patients were NYHA class II (67%) or
NYHA class III (32%) at study onset, and median LVEF was 25%. Enrolled patients had a
high utilization of evidence-based therapies for systolic HF, with 94% receiving β-blockers
and 95% receiving either angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers. Median NT-proBNP levels were 819 pg/mL; median hs-CRP levels were 3.3 mg/
dL, and 13.9% of subjects had cTnT >0.01 μg/mL. There were no statistically significant
differences between the usual care and exercise training groups for any of the variables at
baseline.
Changes in biomarkers with exercise training
There were no statistically significant differences in NT-proBNP (779 vs 694, P = .59), hs-
CRP (3.4 vs 3.2, P = .34), or the proportion of subjects with cTnT elevation (14.4% vs
14.7%, P = .91) at 3 months between the exercise training and usual care groups. Exercise
training did not influence biomarker levels at 3 months, even after controlling for baseline
levels of NT-proBNP (P = .10) or hs-CRP (P = .80). Similarly, there was no association
between exercise training and control groups with regard to the prevalence of elevated cTnT
levels at 3 months (P = .83). Figure 1A and B shows scatter plots of baseline and 3-month
measurements for both NT-proBNP and hs-CRP according to treatment group. Figure 1C
shows bar graphs of the number of patients in each category of baseline and 3-month cTnT
status.
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Volume of exercise and biomarker changes
Patients were grouped according to achieved level of exercise at 3 months in the exercise
training group: low exercise (<3 MET-hours/week), moderate exercise (3-7 MET-hours/
week), and high exercise (>7 MET-hours/week). When compared with patients in the low
exercise group, those in the moderate and high exercise group had decreased risk of all-
cause mortality and hospitalizations (hazard ratio [HR] 0.58, 95% CI [0.43-0.78] and HR
0.55, 95% CI [0.35-0.860], respectively). Although levels of both NT-proBNP and hs-CRP
levels were progressively lower among patients who were able to achieve higher levels of
exercise, the differences between baseline and 3-month levels of either biomarker within
each exercise category were not significantly different (Figure 2). We were unable to test
this hypothesis in the case of cTnT due to the small number of patients who experienced a
change from high to low across exercise volume groups.
Changes in biomarker levels, exercise capacity, and long-term outcomes
Next, we examined the relationships between improvements in biomarker levels, changes in
maximal exercise capacity (peak VO2), and clinical outcomes. For patients in whom NT-
proBNP levels decreased at 3 months, there was a concomitant increase in peak VO2 (P ≤ .
001) (Figure 3A). Improvements in hs-CRP or cTnT were not associated with increases in
peak VO2 (P = .08: Figure 3B, P = .78, Figure 3C).
Improved NT-proBNP levels at 3 months were associated with reduced risk of all 3
composite clinical outcomes: (1) all-cause mortality or all-cause hospitalization, (2) all-
cause mortality, and (3) cardiovascular mortality or cardiovascular hospitalization (P ≤ .04
all) (Table II). This decrease in risk persisted even after controlling for a comprehensive set
of previously identified predictors for each outcome from the overall HF-ACTION cohort
(Supplementary Table II).13 Improvements in cTnT were associated with decreased risk of
all-cause mortality (P = .03) that did not persist in the fully adjusted analysis. There were no
associations between reductions in hs-CRP and clinical outcomes.
Discussion
Findings from this study challenge the hypothesis that exercise training improves commonly
evaluated cardiovascular biomarkers in patients with chronic HF. We found that plasma
levels of NT-proBNP, hs-CRP, or cTnT did not significantly improve at 3 months despite a
structured exercise training program, even after accounting for baseline biomarker levels.
Although patients who tended to exercise more had lower levels of NT-proBNP and hs-CRP
and decreased risk of adverse clinic outcomes, volume of exercise did not influence serial
levels. Only decreases in NT-proBNP translated to improvements in functional capacity and
reductions in risk of clinical outcomes.
We believe that these data have important clinical implications as biomarker-guided therapy
becomes more routine in the management of chronic HF, and effects of key therapeutic
interventions on serial biomarker levels require clarification. Although exercise training has
a class 1 recommendation by both the 2012 European Society of Cardiology and 2013
American College of Cardiology/American Heart Association guidelines for treatment of
chronic HF, its effects on serial levels of commonly measured cardiovascular biomarkers are
unclear.1,2 This study, an analysis of the definitive trial of exercise training in HF that led to
the recommendations above, is the first to have standardized ascertainments of detailed
exercise data and serial biomarker measurements on HF patients randomized to exercise
interventions versus standard of care and found no meaningful effect of exercise on serial
levels.
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The most immediate clinical implications of our results relate to the use of exercise to
reduce natriuretic peptide levels in patients with chronic HF, a strategy that has been
perpetuated in the literature as accepted wisdom.1,5 In terms of the individual patients, our
findings would suggest that any changes in NT-proBNP levels with exercise training would
be minimal and the alternative therapies might be more efficacious for this purpose.
Although our negative results in regard to the independent effects of exercise on NT-
proBNP are at odds with most published studies, previous randomized studies examining
this question were small (largest n = 71 patients) and varied significantly in design,
methodology, and patient characteristics.14 A recently published meta-analysis of 10 studies
that included 565 patients found exercise to decrease natriuretic peptide levels; however,
understanding the results needs cautious interpretation of the data as well as confirmation
within a randomized trial, which the current study provides using almost twice as many
participants (n = 928).15,16 Lastly, an observational study of 2,933 patients with HF looked
at the effects of physical activity on NT-proBNP levels, finding evidence of an inverse
relationship between NT-proBNP levels and amount of self-reported physical activity.17,18
Our results confirm the negative correlation between volume of exercise and biomarker
levels, but not an association between exercise training and improvements in biomarker
levels. This implies that the suggested causal relationship between activity and lower NT-
proBNP levels may have resulted from false-positive associations, a common drawback of
observational studies.17
Although inflammation and myonecrosis play a central role in the pathogenesis of chronic
HF, only a handful of studies have reported on changes in hs-CRP and cTnT with exercise in
patients. These studies have not included patients with established HF; to our knowledge,
this is the first look at the effects of exercising training on serial hs-CRP and cTnT levels in
this patient population.19-22 Our results suggest that serial measurements of these
biomarkers may not be reliable surrogates for any health benefits of physical activity in this
patient population.
Our findings that serial improvements in NT-proBNP lead to reduced risk of clinical
outcomes have been previously described in the literature.23,24 The fact that our results are
consistent with previous findings adds credence to the notion that our null results in regard
to NT-proBNP changes with exercise training may be accurate. We also report on a lack of
association between reductions in hs-CRP and cTnT and changes in peak VO2 or lowered
risk of clinical outcomes. The incremental clinical value of serial hs-CRP measurements in
HF patients has never been well studied, and these findings will require future confirmation;
however, they reflect results of a recent study showing no predictive value of serial hs-CRP
levels in high-risk patients without HF.25,26 Lastly, our negative findings in regard to serial
cTnT levels run counter to some previous studies.27,28 However, results of studies
examining this question have varied tremendously, depending on the patient population
studied, the troponin assay used, or the study design.29 There is currently no clear consensus
on the use of cTnT measurements in chronic HF, and the results presented here raise the
need for a closer examination of the prognostic implications of serial troponin measurements
in HF.29,30
There are potential limitations to the present study. The population for this study was
derived from the HF-ACTION trial and is susceptible to the limitations inherent in clinical
trial populations. Biomarker measurements were made after 3 months of structured exercise
training, and there is a possibility that changes in levels might have been noted after a longer
exercise period. Our study population consisted only of patients with impaired ejection
fraction (LVEF <35%), so our results cannot be extrapolated to the population of patients
with HF and preserved ejection fraction. Our population consisted of ambulatory patients
with NYHA class II and III HF, and these findings may not be generalizable to patients with
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less or more severe illness. We used a commonly used platform for measurement of cTnT,
rather than the newer high sensitivity assays used in more recent studies of troponin
elevation in HF.30
In conclusion, a 3-month structured exercise training program did not lead to improvements
in plasma concentrations of NT-proBNP, hs-CRP, and cTnT, compared with usual care, in a
cohort of stable chronic systolic HF patients. Baseline biomarker levels or volume of
exercise did not alter these findings. Serial improvements in NT-proBNP, but not hs-CRP or
cTnT levels, were associated with increases in peak VO2 levels and decreased risk of
adverse clinical outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Baseline and 3-month biomarker levels according to treatment group. Scatter plots depicting
the baseline (x-axis) and 3-month (y-axis) measurements of log-transformed NT-proBNP
(A) and hs-CRP (B), according to treatment assignment. C, Frequency distributions of
baseline (left) and 3-month (right) cTnT, according to treatment assignment.
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Baseline and 3-month biomarker levels according to amount of exercise. Median and
intraquartile ranges of baseline and 3-month values for NT-proBNP and hs-CRP, according
to amount of exercise. P values indicate whether levels between baseline and 3 months are
statistically different.
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Change in baseline and 3-month peak VO2 according to biomarker improvement. Scatter
plots depicting the baseline (x-axis) and 3 month (y-axis) measurements of log-transformed
peak VO2 according to levels of NT-proBNP (A), hs-CRP (B), and cTnT (C), grouped
according to biomarker improvement versus no improvement at 3-month follow-up.
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Table I
Baseline characteristics of study participants
Overall population (n = 928) Usual care (n = 451) Exercise training (n = 477) P
Age, y 59.0 (50.9, 68.0) 59.0 (50.7, 68.0) 59.0 (51.2, 67.9) .919
Sex, % woman 272/928 (29.3%) 120/451 (26.6%) 152/477 (31.9%) .079
Race (% white) 573/912 (62.8%) 286/446 (64.1%) 287/466 (61.6%) .354
History of diabetes 303/928 (32.7%) 145/451 (32.2%) 158/477 (33.1%) .752
History of MI 380/928 (40.9%) 191/451 (42.4%) 189/477 (39.6%) .398
History of hypertension 568/922 (61.6%) 261/449 (58.1%) 307/473 (64.9%) .034
Current smoker 145/924 (15.7%) 78/449 (17.4%) 67/475 (14.1%) .344
NYHA class
 II 619/928 (66.7%) 306/451 (67.8%) 313/477 (65.6%)
 III 301/928 (32.4%) 143/451 (31.7%) 158/477 (33.1%) .382
 IV 8/928 (0.9%) 2/451 (0.4%) 6/477 (1.3%)
Resting ECG conduction
 Normal 376/914 (41.1%) 184/443 (41.5%) 192/471 (40.8%)
 LBBB 161/914 (17.6%) 78/443 (17.6%) 83/471 (17.6%) .975
 RBBB 35/914 (3.8%) 15/443 (3.4%) 20/471 (4.2%)
 IVCD 123/914 (13.5%) 60/443 (13.5%) 63/471 (13.4%)
 Paced 219/914 (24.0%) 106/443 (23.9%) 113/471 (24.0%)
Creatinine, mg/dL 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) 1.2 (1.0, 1.5) .835
Blood urea nitrogen, mg/dL 21.0 (15.0, 28.0) 21.0 (15.0, 29.0) 20.5 (15.0, 27.0) .911
Hemoglobin level, g/dL 13.3 (12.3, 14.5) 13.4 (12.3, 14.6) 13.3 (12.1, 14.5) .252
NT-proBNP, pg/mL (B) 818.8 (346.0, 1818) 853.2 (374.6, 1829) 762.3 (310.5, 1809) .221
NT-proBNP, pg/mL (3 M) 726.1 (281.6, 1753) 778.5 (296.7, 1825) 693.7 (276.1, 1725) .593
hs-CRP, mg/dL (baseline) 3.3 (1.5, 7.8) 3.4 (1.6, 7.9) 3.2 (1.4, 7.5) .321
hs-CRP, mg/dL (3 M) 3.3 (1.5, 7.6) 3.6 (1.6, 7.8) 3.1 (1.4, 7.4) .348
Troponin T >0.01 μg/mL (B) 129/928 (13.9%) 63/451 (14.0%) 66/477 (13.8%) .954
Troponin T >0.01 μg/mL (3 M) 135/928 (14.5%) 65/451 (14.4%) 70/477 (14.7%) .910
LVEF, % 24.6 (20.0, 30.2) 24.7 (20.0, 30.5) 24.5 (20.0, 30.1) .606
Severe or moderate MR 105/928 (11.3%) 52/451 (11.5%) 53/477 (11.1%) .840
Exercise duration, min 10.0 (7.2, 12.0) 10.0 (7.4, 12.3) 9.8 (7.0, 12.0) .302
Peak VO2 in mL/kg/min 14.5 (11.8, 17.5) 14.7 (12.0, 17.7) 14.4 (11.4, 17.4) .183
6-min walk distance, m 376.4 (304.8, 433.7) 374.3 (312.1, 428.2) 378.1 (297.2, 441.6) .930
β-Blocker 869/928 (93.6%) 428/451 (94.9%) 441/477 (92.5%) .127
ACE or ARB 881/928 (94.9%) 428/451 (94.9%) 453/477 (95.0%) .962
Aldosterone antagonist 399/928 (43.0%) 189/451 (41.9%) 210/477 (44.0%) .515
Antiarrhythmic therapy 132/927 (14.2%) 66/451 (14.6%) 66/476 (13.9%) .738
Digoxin 432/928 (46.6%) 219/451 (48.6%) 213/477 (44.7%) .233
ICD at baseline 411/928 (44.3%) 193/451 (42.8%) 218/477 (45.7%) .373
Values are median (interquartile range) or n (%). Abbreviations: MI, Myocardial infarction; MR, mitral regurgitation; B, baseline; 3M, 3 months;
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ICD, implantable cardiac defibrillator.
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